SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage
biopharmaceutical company with a novel immunotherapy platform that
produces specifically targeted, high-potency, fully-human
immunoglobulin (hIgG) antibodies (fully-human polyclonal
antibodies) without the need for human donors, today announced that
Eddie J. Sullivan, Ph.D., co-founder, President and Chief Executive
Officer of SAB Biotherapeutics will present at the BIO 2023
International Convention. The conference, known as the world's
largest and most influential event for the pharmaceutical and
biotechnology industry, will take place from June 5 to June 8, 2023
at the Boston Convention and Exhibition Center in Boston, Mass.
During the presentation, titled "Therapeutic
immunoglobulin (hIgG) for pre- and post-exposure prophylaxis and
treatment of influenza," Dr. Sullivan will primarily discuss
SAB-176, a fully-human polyclonal antibody therapeutic for the
treatment of Type A and Type B influenza infections. Dr. Sullivan
will present positive clinical data supporting the use of SAB-176
as an effective treatment option for influenza, along with insights
into the recent Breakthrough Therapy and Fast Track Designations
granted by the U.S. Food and Drug Administration (FDA). He will
provide a comprehensive overview of SAB's proprietary DiversitAb™
immunotherapy platform, which utilizes genetically modified
bovines, called Transchromosomic (TC) Bovine™, to produce
fully-human hIgG antibodies. Additionally, Dr. Sullivan will touch
upon other notable pipeline therapies, including SAB-185, a
potential treatment for COVID-19 with recent positive Phase 3 trial
results. SAB is seeking out-licensing and partnering opportunities
for SAB-176 and SAB-185 programs.
The presentation will take place on
Wednesday, June 7, at 3:45 pm in Room 104B.
“We look forward to presenting our platform’s
latest advancements and research progress at BIO 2023,” Dr.
Sullivan said. “SAB Biotherapeutics is on a transformative journey,
leveraging our novel immunotherapy platform to develop innovative
therapeutic solutions like SAB-176, which holds tremendous promise
in the treatment of influenza. We eagerly anticipate engaging with
global leaders at this influential gathering to share insights on
our robust pipeline, foster meaningful connections, discuss
out-licensing and partnering opportunities and contribute to
advancing population health.”
The annual BIO International Convention, hosted
by Biotechnology Innovation Organization (BIO), is the world's
largest industry gathering and brings together thousands of global
biotechnology and biopharmaceutical leaders. The four-day in-person
event includes networking, programming, and partnering
opportunities. The convention features more than 100 educational
sessions and 500 experts who cover diverse, relevant topics,
including business development and finance opportunities,
healthcare innovations, the future of biotechnology, and the
regulatory and policy landscape.
To learn more about partnering opportunities and
SAB’s presence at BIO 2023, please contact Sheila Carlson at
scarlson@sab.bio.
About SAB Biotherapeutics,
Inc.
SAB Biotherapeutics, Inc. (SAB) is a
clinical-stage biopharmaceutical company focused on the development
of powerful and proprietary immunotherapeutic polyclonal human
antibodies to treat and prevent infectious diseases and immune and
autoimmune disorders. Our development programs include infectious
diseases resulting from outbreaks and pandemics, as well as
immunological, gastroenterological, and respiratory diseases that
have significant mortality and health impacts on immune compromised
patients. SAB has applied advanced genetic engineering and antibody
science to develop Transchromosomic (Tc) Bovine™. Our versatile
DiversitAb™ platform is applicable to a wide range of serious unmet
needs in human diseases. It produces natural, specifically
targeted, high-potency, fully-human polyclonal immunotherapies
without the need for human donors. SAB currently has multiple drug
development programs underway and collaborations with the US
government and global pharmaceutical companies. For more
information on SAB, visit: https://www.SAb.bio/ and follow SAB on
Twitter and LinkedIn.
Forward-Looking Statements
Certain statements made herein that are not
historical facts are forward-looking statements for purposes of the
safe harbor provisions under The Private Securities Litigation
Reform Act of 1995. Forward-looking statements generally are
accompanied by words such as “believe,” “may,” “will,” “estimate,”
“continue,” “anticipate,” “intend,” “expect,” “should,” “would,”
“plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook”
and similar expressions that predict or indicate future events or
trends or that are not statements of historical matters. These
forward-looking statements include, but are not limited to,
statements regarding future events, the development and efficacy of
our influenza program, C. diff. program, type 1 diabetes program,
and other discovery programs, the results, including timing, of the
development of SAB-176, SAB-185, SAB-142 and SAB-195, including
SAB-176 Fast Track designation and Breakthrough Therapy
designation, and the outcome of potential future government and
other third-party collaborations or funded programs.
These statements are based on the current
expectations of SAB and are not predictions of actual performance,
and are not intended to serve as, and must not be relied on, by any
investor as a guarantee, prediction, definitive statement, or an
assurance, of fact or probability. These statements are only
current predictions or expectations, and are subject to known and
unknown risks, uncertainties and other factors which may be beyond
our control. Actual events and circumstances are difficult or
impossible to predict, and these risks and uncertainties may cause
our or our industry’s results, performance, or achievements to be
materially different from those anticipated by these
forward-looking statements. A further description of risks and
uncertainties can be found in the sections captioned “Risk Factors”
in our most recent annual report on Form 10-K, subsequent quarterly
reports on Form 10-Q, and other filings with or submissions to, the
U.S. Securities and Exchange Commission, which are available at
https://www.sec.gov/. Except as otherwise required by law, SAB
disclaims any intention or obligation to update or revise any
forward-looking statements, which speak only as of the date they
were made, whether as a result of new information, future events,
or circumstances or otherwise.
Investor
Relations:matt@milestone-advisorsllc.com
Media Relations:SABPR@westwicke.com
SAB Biotherapeutics (NASDAQ:SABSW)
Historical Stock Chart
From Sep 2024 to Oct 2024
SAB Biotherapeutics (NASDAQ:SABSW)
Historical Stock Chart
From Oct 2023 to Oct 2024